R 1663
Alternative Names: R1663Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Roche
- Class Anticoagulants; Antithrombotics; Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in USA (PO)
- 28 Aug 2012 Roche completes a phase I trial in Healthy volunteers in United Kingdom